How Lilly is piecing it together
Eli Lilly & Co. has been quietly assembling a women's health portfolio, hiring experts and evaluating drugs for targets like osteoporosis and endometriosis, people with knowledge of the plans said. The company has recruited scientists for osteoporosis and preeclampsia, and expanded the remit of veteran leaders to include women's health. A recent listing described new discovery capabilities for pregnancy-related conditions as part of a "growing Women's Health strategy."
Lilly's playing the long game here: set up teams and infrastructure first, then unveil a bigger strategy or splashy deal once the foundation is in place.
Why now, and where the money comes from
Over the past few years, Lilly has concentrated on four primary areas: cardiometabolic health, neuroscience, cancer, and immunology. Lately it has layered on early-stage buys and hires in places it thinks it can move the needle, like infectious diseases and emerging platforms such as psychedelics. Women's health looks poised to join that list.
On average, analysts project that sales from the cardiometabolic portfolio - featuring Mounjaro and Zepbound - could approach about $70 billion by 2026. The boom has also boosted interest across the sector: both Lilly and Novo Nordisk A/S are studying how their medicines perform for women across life stages, including during and after menopause, and even in conditions such as polyendocrine metabolic ovarian syndrome, or PMOS, which can cause infertility.
Who's driving it and what they're saying
In May, Lilly appointed reproductive medicine specialist Kelle Moley to run its women's health efforts and oversee early clinical development. According to Lilly's group vice president overseeing Cardiometabolic Health Research, Ruth Gimeno, "At Lilly, we see a real opportunity to advance women's health, through medicines in our existing therapeutic areas, but also by accelerating research into new areas." "Too many women's health conditions have gone under-researched for too long, and we are committed to broadening the women's health ecosystem and to advance science in areas of serious unmet need."
Earlier this year, Chief Executive Officer Dave Ricks said the company is setting up an internal effort to evaluate women's health uses within its obesity drug lineup, comments he made during a discussion with physician and influencer Jen Ashton. And Kenneth Custer, who leads Lilly's cardiometabolic business, put it bluntly in May: weight-loss drugs are "kicking off a new era of women's health," adding, "I do think there's a big opportunity in women's health."
Investing in long term themes means balancing curiosity with protecting your financial foundation. Join Briefs Finance CEO Jaspreet Singh on September 29th for a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, where he shows how we're spotting investment opportunities as the dollar falls. Save your spot.
Deals, investor interest, and what to watch next
Lilly has been active outside its own labs. It put $40 million into Absci Corp. as a strategic investment. Absci is developing an early-stage endometriosis therapy intended to interfere with a biological signal believed to drive lesion growth and pain; Lilly also added a company representative to Absci's endometriosis advisory board. "Dave Ricks and team are being very courageous in going into an area that I think most pharma would've never gone into and taking bets and risks," Absci CEO Sean McClain said.
In May, Lilly announced plans to buy LimmaTech Biologics, a company developing vaccines targeting multiple bacterial pathogens, including ones that "drive infertility and other long-term consequences of infection that fall disproportionately on women." The company isn't starting from zero here: it already has a sizable breast cancer franchise and previously helped shape the osteoporosis market with drugs like Forteo and Evista.
Investor appetite is rising too. Although women and girls are nearly half the global population, women's health has historically attracted only 6% of private health-care investment, per the World Economic Forum. That's changing, said Diamantis Xylas, Catalio Capital Management's head of research, noting hotter interest in endometriosis and bone health; Catalio recently backed Entera Bio, which is working on an osteoporosis treatment.
One more tell: experts warn rapid weight loss may weaken bones, particularly in older women. While data is mixed, that concern could lift demand for bone-protective therapies.
What this could mean for your money
Lilly's methodical buildout suggests more targeted bets instead of one mega-acquisition, with early hiring, partnerships, and tuck-in deals setting the stage. The stock inched up by under 1% as trading got underway in New York on Thursday. If this momentum holds, future catalysts could come from pregnancy-related disorders and endometriosis - areas that have been overlooked and where unmet need is high.
Healthy portfolios watch evolving industries while staying disciplined to grow and preserve capital. Our CEO Jaspreet Singh is hosting a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, on September 29th. Sign up free to join him live.
